Lorraine V. Kalia, MD, PhD, FRCPClorraine.firstname.lastname@example.org
Lorraine Kalia, MD, PhD, FRCPC is a scientist at the Krembil Research Institute, University Health Network and Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto. She is an associate professor in the Division of Neurology, Department of Medicine, University of Toronto. As a movement disorders neurologist, she specializes in Parkinson’s disease and related movement disorders at the Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program at Toronto Western Hospital, University Health Network.
Suneil K. Kalia, MD, PhD, FRCSCsuneil.email@example.com
Suneil Kalia, MD, PhD, FRCSC is a scientist at the Krembil Research Institute and KITE Research Institute, University Health Network and an associate professor in the Division of Neurosurgery, Department of Surgery, University of Toronto. As a stereotactic and functional neurosurgeon, he focuses on the surgical management of movement disorders, epilepsy, and pain.
I received my BSc in Pharmacology from the University of Aberdeen in 2011 and my PhD at the biotechnology company TauRx Therapeutics, a spin-off company at the University of Aberdeen. My PhD investigated the effects of novel tau aggregation inhibitors in tau transgenic mouse models of Alzheimer’s disease, targeting cholinergic and glutamatergic impairment. In 2019, I joined the Kalia labs to study molecular mediators of α-synuclein and to investigate potential repurposing of currently approved therapies for Parkinson’s disease. My goals are to research and develop potential disease-modifying treatments for Parkinson’s disease with a specific interest on industry collaboration and clinical translation.
I completed my BSc in Biotechnology from Bangalore University, India in 2009, followed by my Master’s in Molecular Medicine from University of Sheffield, UK in 2010. After this I went on to do my Ph.D. in Experimental Biology and Neuroscience from the University of Coimbra, Portugal, and University of Bordeaux, France, where I worked in deciphering the interaction of Purines with Neuron-Glia in Neuroinflammation. My first postdoctoral fellowship was at Northwestern University, US, unravelling the role of autophagy in neurodegeneration. I joined the Kalia lab in 2021 to be part of their ongoing research to uncover the molecular and cellular mechanisms of neurodegeneration in Parkinson’s Disease.
I received my BHSc from McMaster University in 2010. I subsequently pursued a PhD in Neuroscience focusing on characterizing the role of brain-reactive autoantibodies in a model of neuropsychiatric lupus in Dr. Boris Sakic’s lab. I graduated in November 2015 and began a postdoctoral fellowship with Dr. Margaret Fahnestock, coordinating a collaborative project examining epigenetic factors and immune mechanisms underlying sex differences in behaviour and pathology in a mouse model of Alzheimer’s disease. I joined the Kalia labs in 2018 and my current research focuses on characterizing the molecular chaperone pathways involved in Parkinson’s disease.
I completed my Bachelor’s degree in Biochemistry from Keele University, UK in 2013 followed by a Master’s in Neuropharmacology at Nottingham Trent University, UK in 2016. I started my PhD in 2016 at the University of Warwick, UK and completed in 2020. My PhD focused on investigating the molecular functions of the small GTPase activating protein, ArfGAP3, in autophagy using Drosophila melanogaster as a model organism. I joined the Kalia labs in 2021 to study the molecular mechanisms of Parkinson’s disease.
I completed my Bachelor’s degree in Pharmacy in 2012 from Mumbai University, India. I pursued my Master’s degree in Pharmacology from Northeastern University in Boston, USA in 2013 and transitioned to the PhD program in 2016. I graduated with my PhD in Pharmacology in 2019. My PhD project focussed on developing a transnasal mucosal drug delivery method to administer oligonucleoties to the brain, bypassing the blood-brain barrier. I joined the Kalia labs in 2019 to investigate innovative therapeutic strategies for Parkinson’s disease.
I completed my Undergraduate Bachelor of Medical Sciences Degree from Western University. I am currently a MSc candidate and my project examines the effects of chaperone proteins on mitochondrial autophagy.
I received my BSc in Neuroscience from the University of Toronto. I am currently a MSc candidate and my project focuses on post-translational modifications of chaperone proteins.
I am a medical doctor from Bangladesh. I have completed my MSc. in the University of Manitoba and currently, pursuing a PhD. in Kalia’s lab. I am exploring the role of RNA binding proteins in α-synuclein mediated neurodegeneration in Parkinson’s Disease.
I obtained my BSc from the University of Toronto, specializing in Molecular Biology and Genetics, and my MSc from the Biology Department at McGill University. I have worked as a research technician in labs studying cancer biology, renal physiology, and neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. My current research interest is to better understand the molecular mechanisms underlying Parkinson’s disease with the goal to find disease-modifying therapies.
I received my MD degree from Hokkaido University, Japan and my PhD in medical science (pharmacology) from Kyoto University, Japan. I learned C. elegans genetics as a postdoctoral fellow and worked in Joe Culotti’s lab at University of Toronto. After Joe confirmed that I had learned everything he could teach me, I moved back to Japan as a research associate at Tokyo Women’s Medical University. Missing Canada, I rejoined the Culotti lab and then moved to the Kalia labs in 2017 to continue my research. I have a strong belief in the power of C.elegans genetics to define the signalling patways involved in the maintenance of healthy neurons.
Cloner of genes, modifier of genomes. Received a BSc in Genetics from the University of Guelph in the era when pBR 322 was a hot new vector and Maxam–Gilbert sequencing was all the rage. Was part of the team that identified mutations in copper-zinc superoxide dismutase as the causative agent for a familial form of amyotrophic lateral sclerosis (fALS). Currently building molecular reagents to assist the lab in better understanding the cause of Parkinson’s disease.
|Name||Role in the lab|
|K. S. Chen||MSc student|
|A. De Goyon Pelard||Intern|
|P. De Guzman||BSc student|
|M. L. De Snoo||MSc student|
|M. Duggal||Research Analyst|
|D. Ellner Yerushalmi||BSc student|
|R. Faidi||BSc student|
|S. M. Fereshtehnejad||Intern|
|E. L. Friesen||MSc student|
|P. Gros||Neurology resident|
|M. Hamani||BSc student|
|G. Heymann||MSc student|
|V. Hucik||BSc student|
|S. Ihn||BSc student|
|S. Ishikura||BSc student|
|K. Jarrah||BSc student|
|D. J. Lee||Postdoctoral fellow|
|E. J. Lee||Postdoctoral fellow|
|S. X. Li||MSc student|
|K. Liu||BSc student|
|C. Lozano||BSc student|
|N. Mahbub||BSc student|
|C. McKinnon||Postdoctoral fellow|
|K. Menezes||MSc student|
|S. M. Mylvaganam||BSc student|
|S. G. Ngana||MD student|
|D. O’Hara||Postdoctoral fellow|
|L. M. Oliveira||Postdoctoral fellow|
|N. Patel||MD student|
|J. K. Perera||MD student|
|S. Ping||MSc student|
|P. Ramanujam||BSc student|
|K. Rosborough||MD student|
|A. Sabean||BSc student|
|P. Saleh||Neurology resident|
|A. Sebastian||BSc student|
|N. Tabassum||BSc student|
|M. Tereshchenko||BSc student|
|L. Tessier||BSc student|
|B. A. Yeung||BSc student|
|Y. T. Zhang||MSc student|